Intestinal Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INT068 MIFTS: 52	Intestinal Disease Categories: Gastrointestinal diseases, Metabolic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Intestinal Disease

MalaCards integrated aliases for Intestinal Disease:

Name: Intestinal Disease ¹¹ ¹⁴ ¹⁶ ⁷⁵

Intestinal Diseases ⁴³ ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the digestive system

Other diseases of intestines

Other diseases of intestine

Disease of intestine, unspecified

ICD11: ³³

Diseases of the digestive system

Diseases of small intestine

Intestinal malabsorption or protein-losing enteropathy

Intestinal malabsorption

Intestinal failure

External Ids:

Disease Ontology ¹¹ DOID:5295

ICD9CM ³⁴ 569.9

MeSH ⁴³ D007410

NCIt ⁴⁹ C26801

SNOMED-CT ⁶⁸ 266483008

ICD10 ³¹ K63.9

EFO ¹⁶ EFO_0009431

ICD11 ³³ 778202494

UMLS ⁷¹ C0021831

Sources

Summaries for Intestinal Disease

Disease Ontology: ¹¹ A gastrointestinal system disease that is located in the intestine.

MalaCards based summary: Intestinal Disease, also known as intestinal diseases, is related to crohn's disease and colonic disease, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cell differentiation - expanded index and DNA damage response (only ATM dependent). The drugs Prucalopride and Copper have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and bone marrow.

Sources

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure	Congenital Intestinal Disease Due to an Enzymatic Defect
Intestinal Disease Due to Fat Malabsorption	Intestinal Disease Due to Vitamin Absorption Anomaly
Rare Intestinal Disease

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 702)

#	Related Disease	Score	Top Affiliating Genes
1	crohn's disease	32.4	MIR31 MIR21 MIR196A1 MIR142 ICOSLG H2AC18
2	colonic disease	32.4	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
3	gastrointestinal system disease	31.5	MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
4	intestinal benign neoplasm	31.2	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
5	lymphoma, mucosa-associated lymphoid type	31.0	TP53 SDC1 MIR155 MIR142 ICOSLG CCR6
6	lymphoma, hodgkin, classic	31.0	TP53 MIR21 MIR155 ICOSLG H2AC18 CCR6
7	immune deficiency disease	31.0	MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
8	marginal zone b-cell lymphoma	30.9	SDC1 MIR142 ICOSLG CCR6 BCL6
9	viral infectious disease	30.9	MIR21 MIR199A1 MIR155 ICOSLG H2AC18 CCR6
10	colonic benign neoplasm	30.8	TP53 MIR21 MIR199A1 MIR145 MIR143 H2AC18
11	cholangitis, primary sclerosing	30.8	TP53 MIR199A1 ICOSLG CCR6
12	lymphoma, non-hodgkin, familial	30.8	TP53 SDC1 MIR518A1 MIR31 MIR21 MIR199A1
13	deficiency anemia	30.8	TP53 MIR126 ICOSLG H2AC18 CCR6
14	diffuse large b-cell lymphoma	30.7	MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR145
15	sclerosing cholangitis	30.7	MIR199A1 ICOSLG CCR6
16	colorectal cancer	30.7	TP53 SDC1 MIR31 MIR21 MIR199A1 MIR196A1
17	head and neck cancer	30.6	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
18	pancreatic ductal adenocarcinoma	30.6	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
19	eye disease	30.6	TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR17
20	kidney cancer	30.6	TP53 MIR21 MIR199A1 MIR193A MIR17 MIR145
21	dermatitis, atopic	30.6	MIR21 MIR155 MIR142 ICOSLG CCR6
22	bone disease	30.6	MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR143
23	spinal cord disease	30.6	TP53 MIR199A1 MIR196A1 MIR155 MIR142 MIR126
24	leukemia, acute myeloid	30.5	TP53 SDC1 MIR31 MIR21 MIR199A1 MIR196A1
25	esophageal cancer	30.5	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
26	vascular disease	30.5	TP53 MIR21 MIR199A1 MIR145 MIR143 MIR126
27	leukemia, acute lymphoblastic	30.5	TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
28	skin disease	30.5	TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
29	myopathy	30.5	MIR21 MIR199A1 MIR196A1 MIR142 MIR126 ICOSLG
30	coccidiosis	30.5	ICOSLG H2AC18 CCR6
31	pulmonary disease, chronic obstructive	30.5	MIR21 MIR199A1 MIR17 MIR142 MIR126 ICOSLG
32	ovarian disease	30.5	TP53 MIR518A1 MIR21 MIR199A1 MIR17 MIR155
33	colorectal adenoma	30.5	TP53 MIR31 MIR21 MIR193A MIR17 MIR143
34	colorectal adenocarcinoma	30.5	TP53 MIR31 MIR193A MIR17 MIR145 MIR143
35	food allergy	30.5	ICOSLG CCR6 AOC1
36	gallbladder disease	30.5	TP53 MIR199A1 MIR196A1 MIR193A MIR17 MIR145
37	bladder cancer	30.5	TP53 MIR31 MIR21 MIR199A1 MIR17 MIR145
38	contact dermatitis	30.5	MIR21 MIR155 MIR142 ICOSLG CCR6
39	diabetes mellitus	30.4	TP53 MIR21 MIR17 MIR155 MIR145 MIR143
40	parasitic helminthiasis infectious disease	30.4	MIR21 ICOSLG H2AC18 CCR6
41	gastric cancer	30.4	TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
42	non-alcoholic steatohepatitis	30.4	MIR21 MIR199A1 MIR142 CCR6
43	endometriosis	30.4	TP53 MIR199A1 MIR17 MIR145 MIR143 MIR142
44	alcohol use disorder	30.4	MIR199A1 MIR196A1 H2AC18 CCR6
45	allergic disease	30.4	MIR21 MIR155 ICOSLG H2AC18 CCR6 AOC1
46	anus cancer	30.4	TP53 H2AC18 CCR6
47	intestinal schistosomiasis	30.4	MIR199A1 ICOSLG CCR6
48	aortic aneurysm, familial abdominal, 1	30.4	MIR21 MIR199A1 MIR126 H2AC18 CCR6
49	burkitt lymphoma	30.4	TP53 MIR21 MIR155 MIR145 MIR143 BCL6
50	systemic scleroderma	30.4	MIR21 MIR142 ICOSLG H2AC18 CCR6

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease	Acute Cystitis
Deficiency Anemia	Esophagitis
Heart Disease	Intestinal Obstruction
Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:

Sources

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:

constipation; diarrhea; signs and symptoms, digestive; anal or rectal pain

Sources

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prucalopride

Approved

Phase 4

179474-81-8

3052762

Copper

Approved, Investigational

Phase 4

7440-50-8

27099

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Mebendazole

Approved, Vet_approved

Phase 4

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 4

110-85-0

4837

Albendazole

Approved, Vet_approved

Phase 4

54965-21-8

2082

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Esomeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6, 119141-88-7

9568614 4594

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Fidaxomicin

Approved

Phase 4

873857-62-6

151383

Simethicone

Approved

Phase 4

8050-81-5

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Golimumab

Approved

Phase 4

476181-74-5

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Neostigmine

Approved, Vet_approved

Phase 4

59-99-4

4456 5824

Glycopyrronium

Approved, Investigational, Vet_approved

Phase 4

596-51-0, 740028-90-4

3494

Ferric maltol

Approved

Phase 4

33725-54-1

Ferrous fumarate

Approved

Phase 4

141-01-5

Infliximab

Approved

Phase 4

170277-31-3

Budesonide

Approved

Phase 4

51333-22-3

5281004 40000 63006

Ascorbic acid

Approved, Nutraceutical

Phase 4

50-81-7

54676860 54670067 5785

DL-alpha-Tocopherol

Approved, Experimental, Investigational, Nutraceutical, Vet_approved

Phase 4

59-02-9, 10191-41-0

2116 14985

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Tocotrienol

Investigational

Phase 4

6829-55-6

9929901

Serotonin Receptor Agonists

Phase 4

Copper Supplement

Phase 4

Tocotrienols

Phase 4

Tocopherols

Phase 4

BB 1101

Phase 4

Antimitotic Agents

Phase 4

Tubulin Modulators

Phase 4

Citrate

Phase 4

Piperazine citrate

Phase 4

DMP 777

Phase 4

157341-41-8

Analgesics

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Interventional clinical trials:

(show top 50) (show all 860)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial	Unknown status	NCT02806206	Phase 4	Prucalopride;Placebo
2	Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease	Unknown status	NCT02774057	Phase 4	Captafer®;Iron Sulfate
3	Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment	Unknown status	NCT02760940	Phase 4	oral liposomal iron
4	Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section	Unknown status	NCT02571881	Phase 4	Oxycodone;oxycodone-naloxone
5	Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate	Unknown status	NCT03860012	Phase 4	Folic Acid
6	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	Unknown status	NCT03220841	Phase 4	Adalimumab Injection;Thiopurine
7	Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome	Unknown status	NCT01312259	Phase 4
8	Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders	Unknown status	NCT01184690	Phase 4
9	Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding	Unknown status	NCT01176864	Phase 4
10	A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial	Completed	NCT03723447	Phase 4	Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
11	Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care	Completed	NCT01314937	Phase 4	Mebendazole
12	Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth	Completed	NCT01748929	Phase 4	Albendazole;Placebo
13	Effect of Intestinal Helminths on Gut Microflora	Completed	NCT01192802	Phase 4	albendazole
14	Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease	Completed	NCT01981889	Phase 4	Prednisone
15	Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program.	Completed	NCT01934088	Phase 4	Propofol;Midazolam;Fentanyl
16	Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea	Completed	NCT03833999	Phase 4	Ondansetron 8mg;Lactulose;Placebo oral capsule
17	Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)	Completed	NCT00640809	Phase 4	Celecoxib;Ibuprofen plus Omeprazole
18	Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial	Completed	NCT04775732	Phase 4
19	Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease	Completed	NCT01908283	Phase 4
20	Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil	Completed	NCT02248337	Phase 4	Colon preparation for colonoscopy
21	Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery	Completed	NCT02573922	Phase 4	oxycodone-naloxone;Oxycodone
22	Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)	Completed	NCT02437591	Phase 4	fidaxomicin
23	A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency.	Completed	NCT01067547	Phase 4	Iron Sucrose.;Iron sucrose
24	The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels	Completed	NCT00167882	Phase 4	5-aminosalicylate (Pentasa, Ferring)
25	Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease	Completed	NCT01034358	Phase 4
26	A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy	Completed	NCT02334631	Phase 4	High Volume Simethicone;Standard Volume Simethicone
27	The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single-Blind, Randomized, Multi-center Study	Completed	NCT02486536	Phase 4	polyethylene glycol
28	Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients	Completed	NCT02461758	Phase 4
29	Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission	Completed	NCT02453776	Phase 4	PRECISION dosing Infliximab
30	Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease	Completed	NCT01341808	Phase 4
31	Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness	Completed	NCT02162862	Phase 4	bupropion-SR
32	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).	Recruiting	NCT04626947	Phase 4
33	A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	Recruiting	NCT03798691	Phase 4
34	Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches	Recruiting	NCT03885713	Phase 4
35	De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring	Recruiting	NCT04646187	Phase 4
36	Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial	Recruiting	NCT05280405	Phase 4	Infliximab
37	Bilateral Mid-Abdominal Transverse Abdominis Plane and Rectus Sheath Blocks Comparing The Use of Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy Procedures.	Recruiting	NCT05224089	Phase 4	Liposomal Bupivicaine/Bupivacaine Admixture;Bupivacaine HCL
38	Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn's Diseases	Recruiting	NCT01793831	Phase 4
39	An Assessor-blinded, Randomized, Controlled, Single Center, Parallel Design Trial With Patient Masking to Compare Early Postoperative Gastric Emptying Associated With Rocuronium Neuromuscular Reversal With Sugammadex Versus Neostigmine in Adults Undergoing Colon and Rectal Surgery	Recruiting	NCT04546672	Phase 4	Sugammadex;Neostigmine
40	Model-informed Infliximab Dose De-escalation Following Earlier Dose Escalation in Adult Patients With Inflammatory Bowel Diseases	Recruiting	NCT04982172	Phase 4	Infliximab
41	Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation	Active, not recruiting	NCT02994836	Phase 4	Anti-TNF discontinuation: Physiological saline solution
42	Chronotherapy in Inflammatory Bowel Disease	Active, not recruiting	NCT04304950	Phase 4	Evening Group;Morning Group
43	Comparison for Efficacy and Safety of Bowel Preparation Between Oral Sulfate Table and 2L-polyethylene Glycol/Ascorbate in Elderly: Multicenter, Prospective, Investigator Single-blinded, Randomized Study	Not yet recruiting	NCT05249335	Phase 4	OST;2L-PEG/Asc
44	Predicting Response to Iron Supplementation in Patients With Inflammatory Bowel Disease During Induction Therapy	Not yet recruiting	NCT05456932	Phase 4	Intravenous iron;Ferric maltol;Ferrous fumarate
45	A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease	Terminated	NCT02566889	Phase 4	Infliximab
46	Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies	Terminated	NCT03866538	Phase 4	Withdrawal of Oral Budesonide
47	Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease	Terminated	NCT00205062	Phase 4
48	Thiopurine Induced Pancreatitis in IBD Patients	Withdrawn	NCT02281799	Phase 4	Azathioprine
49	Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission	Unknown status	NCT02044952	Phase 2, Phase 3	Mesalazine, Tripterygium glycosides
50	A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC	Completed	NCT03509220	Phase 3	PBK-1701TC;Standard oral preparation

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Sources

Genetic Tests for Intestinal Disease

Sources

Anatomical Context for Intestinal Disease

Organs/tissues related to Intestinal Disease:

FMA: Intestine

MalaCards : Small Intestine, Bone Marrow, Colon, Spinal Cord, Bone, Liver, T Cells

Sources

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 2462)

#	Title	Authors	PMID	Year
1	The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. ⁶²	Zheng J...Ng SC	36461896	2022
2	The influence of nutrition on intestinal disease with emphasis on coccidiosis. ⁶²	Bedford MR...Apajalahti JH	35791756	2022
3	Genetic selection of Eimeria parasites in the chicken for improvement of poultry health: implications for drug resistance and live vaccine development. ⁶²	Chapman HD...Blake DP	36102051	2022
4	Efficient oral delivery of water-soluble CT contrast agent using an W1/O/W2 alginate hydrogel matrix. ⁶²	Ren M...Zou A	36201862	2022
5	Pathological mechanism of intestinal mucosal barrier injury of large intestine dampness-heat syndrome rats and the protective effect of Yujin powder. ⁶²	Yao W...Wei Y	36156378	2022
6	Per- and polyfluoroalkyl substances exposure and its influence on the intestinal barrier: An overview on the advances. ⁶²	Li J...Huang Z	36055502	2022
7	The Impacts of Iron Overload and Ferroptosis on Intestinal Mucosal Homeostasis and Inflammation. ⁶²	Huo C...Sun H	36430673	2022
8	Estrogen deficiency aggravates fluoride-induced small intestinal mucosa damage and junctional complexes proteins expression disorder in rats. ⁶²	Jin Y...Wang HW	36252517	2022
9	Advancing intestinal organoid technology to decipher nano-intestine interactions and treat intestinal disease. ⁶²	Bao L...Chen C	36465523	2022
10	Recent Research and Application Prospect of Functional Oligosaccharides on Intestinal Disease Treatment. ⁶²	Xu T...Du Y	36364447	2022
11	Hydrogen Sulfide Metabolizing Enzymes in the Intestinal Mucosa in Pediatric and Adult Inflammatory Bowel Disease. ⁶²	Stummer N...Schneider AM	36421421	2022
12	Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription. ⁶²	Peng V...Colonna M	36279426	2022
13	A new surgical technique for short bowel syndrome. ⁶²	Saeki I...Hiyama E	36329426	2022
14	Apoptotic enteropathy, gluten intolerance, and IBD-like inflammation associated with lipotoxicity in DGAT1 deficiency-related diarrhea: a case report of a 17-year-old patient and literature review. ⁶²	Deolet E...Hoorens A	35763111	2022
15	Antioxidant activity and protective effect of wheat germ peptides in an in vitro celiac disease model via Keap1/Nrf2 signaling pathway. ⁶²	Wang C...Wang F	36192986	2022
16	Pulmonary Crohn's Disease or Crohn's Disease with Lung Sarcoidosis? A Case Report and Literature Review. ⁶²	Vlasceanu S...Savu C	36421591	2022
17	Celiac disease: New therapies on the horizon. ⁶²	Dieckman T...Bouma G	35921776	2022
18	Are Tp-e interval and QT dispersion values important in children with coeliac disease? ⁶²	Birinci H...Elevli M	36278847	2022
19	An improved joint non-negative matrix factorization for identifying surgical treatment timing of neonatal necrotizing enterocolitis. ⁶²	Qi G...Yu G	35575464	2022
20	Circ-ITCH overexpression promoted cell proliferation and migration in Hirschsprung disease through miR-146b-5p/RET axis. ⁶²	Xia RP...Zhou CG	35091706	2022
21	Challenges in the diagnosis of marginal zone lymphoma with symptoms of small intestinal disease: a case report and scoping review of the literature. ⁶²	Markopoulos K...Misselwitz B	36388684	2022
22	Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB. ⁶²	Li Y...Huang L	36043787	2022
23	Treatment of ulcerative colitis with Wu-Mei-Wan by inhibiting intestinal inflammatory response and repairing damaged intestinal mucosa. ⁶²	Yan S...Li J	35947900	2022
24	Compound Heterozygous Myosin 5B (Myo5b) Mutation with Early Onset Progressive Cholestasis and No Intestinal Failure. ⁶²	Vij M...Shah V	34338607	2022
25	The transcription factor Cdx2 regulates inflammasome activity through expression of the NLRP3 suppressor TRIM31 to maintain intestinal homeostasis. ⁶²	Jahan S...Lohnes D	35985421	2022
26	Prevalence and Antimicrobial Resistance of Campylobacter jejuni and Campylobacter coli in Wild Birds from a Wildlife Rescue Centre. ⁶²	Casalino G...Circella E	36290276	2022
27	First DNA sequence proof for the occurrence of bovine adenovirus types 10 and 11 in continental Europe. ⁶²	Vidovszky MZ...Harrach B	36315348	2022
28	Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. ⁶²	Beck LC...Stewart CJ	36163498	2022
29	Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery. ⁶²	Liu N...Luo H	36207740	2022
30	Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota. ⁶²	Scull CE...Wang G	36289287	2022
31	Research progress on natural β-glucan in intestinal diseases. ⁶²	Han X...Gao F	36063888	2022
32	Decorated bacteria and the application in drug delivery. ⁶²	Wu F...Liu J	35817214	2022
33	Intestinal cellular heterogeneity and disease development revealed by single-cell technology. ⁶²	Wang Y...Chen YG	36045190	2022
34	Ji-Chuan decoction ameliorates slow transit constipation via regulation of intestinal glial cell apoptosis. ⁶²	Wang XM...Ding WJ	36160643	2022
35	[Efficacy and safety of adalimumab in patients with Crohn's disease]. ⁶²	Liu YY...Chen H	36008296	2022
36	PARASITOLOGIC AND PATHOLOGIC STUDY OF FREE-RANGING SOUTH AMERICAN RATTLESNAKES (CROTALUS DURISSUS TERRIFICUS) IN BRAZIL. ⁶²	de Oliveira Toledo FA...Santos RL	36214236	2022
37	The Use of Metabolomics as a Tool to Compare the Regulatory Mechanisms in the Cecum, Ileum, and Jejunum in Healthy Rabbits and with Diarrhea. ⁶²	Liu Z...Wang M	36139297	2022
38	Immunoproliferative Small Intestinal Disease Diagnosed by Double-balloon Endoscopy with Biopsy Sampling. ⁶²	Meza MRR...Ishigami M	35135924	2022
39	Utility of Diagnostic Colonoscopy in Pediatric Intestinal Disease. ⁶²	Morita M...Kawaguchi T	36233615	2022
40	Glucocorticoids-Induced Neuropsychiatric Disorders in Patients With Inflammatory Bowel Disease: A Systematic Review. ⁶²	Ali S...Hamid P	36225410	2022
41	Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease. ⁶²	Bos V...De Boer NK	36004414	2022
42	[Nutritional problems in celiac patients. Difficulties in achieving an adequate nutritional status]. ⁶²	Jimenez Ortega AI...Martinez Garcia RM	36040008	2022
43	Severe Protein Loss in a 6-month-old Exclusively Breastfed Infant with Atopic Dermatitis. ⁶²	Masic M...Navratil M	36254543	2022
44	Comparative effects of fresh and sterile fecal microbiota transplantation in an experimental animal model of necrotizing enterocolitis. ⁶²	Prado C...Ritter C	35058059	2022
45	The "whole ingredients extract" of Astragali Radix improves the symptoms of dextran sulfate sodium-induced ulcerative colitis in mice through systemic immunomodulation. ⁶²	Linghu KG...Yu H	36109750	2022
46	[Aseptic nasal septal abscess in patients with ulcerative colitis: two case reports. Case report]. ⁶²	Polyakova IN...Stryuk RI	36286947	2022
47	In vitro effects of the 4-[(10H-phenothiazin-10-yl)methyl]-N-hydroxybenzamide on Giardia intestinalis trophozoites. ⁶²	Oliveira RVF...Gadelha APR	35483428	2022
48	Clinical outcomes of palliative self-expandable metal stent placement in right- and left-sided malignant colon obstruction: A Honam Association for the Study of Intestinal Disease (HASID) multicenter study. ⁶²	Oh HH...Joo YE	36042619	2022
49	Trichopsychodermatology: trichotillomania and trichophagia leading to Rapunzel syndrome. ⁶²	Balawender K...Grabarek BO	36090734	2022
50	PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition. ⁶²	Lin F...Tang X	36016366	2022

Sources

Genes for Intestinal Disease

Genes related to Intestinal Disease (0 elite genes):

(show top 50) (show all 125)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TP53	Tumor Protein P53	Protein Coding	16.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	MIR199A1	MicroRNA 199a-1	RNA Gene	16.36	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
3	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	14.92	DISEASES inferred ¹⁴ ¹⁴
4	SDC1	Syndecan 1	Protein Coding	13.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	BCL6	BCL6 Transcription Repressor	Protein Coding	13.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	MIR21	MicroRNA 21	RNA Gene	13.46	DISEASES inferred ¹⁴ ¹⁴
7	MIR17	MicroRNA 17	RNA Gene	13.24	DISEASES inferred ¹⁴ ¹⁴
8	AOC1	Amine Oxidase Copper Containing 1	Protein Coding	13.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	12.85	DISEASES inferred ¹⁴ ¹⁴
10	H2AC18	H2A Clustered Histone 18	Protein Coding	12.75	DISEASES inferred ¹⁴ ¹⁴
11	MIR31	MicroRNA 31	RNA Gene	12.69	DISEASES inferred ¹⁴ ¹⁴
12	MIR145	MicroRNA 145	RNA Gene	12.67	DISEASES inferred ¹⁴ ¹⁴
13	MIR143	MicroRNA 143	RNA Gene	12.62	DISEASES inferred ¹⁴ ¹⁴
14	MIR196A1	MicroRNA 196a-1	RNA Gene	12.22	DISEASES inferred ¹⁴ ¹⁴
15	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	12.21	DISEASES inferred ¹⁴ ¹⁴
16	MIR142	MicroRNA 142	RNA Gene	12.19	DISEASES inferred ¹⁴ ¹⁴
17	MIR518A1	MicroRNA 518a-1	RNA Gene	12.17	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
18	MIR126	MicroRNA 126	RNA Gene	12.1	DISEASES inferred ¹⁴ ¹⁴
19	MIR193A	MicroRNA 193a	RNA Gene	12	DISEASES inferred ¹⁴ ¹⁴
20	MIR155	MicroRNA 155	RNA Gene	11.9	DISEASES inferred ¹⁴ ¹⁴
21	MIR139	MicroRNA 139	RNA Gene	11.87	DISEASES inferred ¹⁴ ¹⁴
22	MIR125A	MicroRNA 125a	RNA Gene	11.86	DISEASES inferred ¹⁴ ¹⁴
23	MIR34A	MicroRNA 34a	RNA Gene	11.76	DISEASES inferred ¹⁴ ¹⁴
24	MIR18A	MicroRNA 18a	RNA Gene	11.74	DISEASES inferred ¹⁴ ¹⁴
25	MIR140	MicroRNA 140	RNA Gene	11.64	DISEASES inferred ¹⁴ ¹⁴
26	MIR30A	MicroRNA 30a	RNA Gene	11.63	DISEASES inferred ¹⁴ ¹⁴
27	MIR149	MicroRNA 149	RNA Gene	11.61	DISEASES inferred ¹⁴ ¹⁴
28	MIR221	MicroRNA 221	RNA Gene	11.59	DISEASES inferred ¹⁴ ¹⁴
29	MIR9-1	MicroRNA 9-1	RNA Gene	11.58	DISEASES inferred ¹⁴ ¹⁴
30	MIR150	MicroRNA 150	RNA Gene	11.57	DISEASES inferred ¹⁴ ¹⁴
31	MIR204	MicroRNA 204	RNA Gene	11.49	DISEASES inferred ¹⁴ ¹⁴
32	MIR200A	MicroRNA 200a	RNA Gene	11.44	DISEASES inferred ¹⁴ ¹⁴
33	MIR214	MicroRNA 214	RNA Gene	11.43	DISEASES inferred ¹⁴ ¹⁴
34	MIR499A	MicroRNA 499a	RNA Gene	11.42	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
35	MIR338	MicroRNA 338	RNA Gene	11.38	DISEASES inferred ¹⁴ ¹⁴
36	MIR144	MicroRNA 144	RNA Gene	11.3	DISEASES inferred ¹⁴ ¹⁴
37	MIR29A	MicroRNA 29a	RNA Gene	11.26	DISEASES inferred ¹⁴ ¹⁴
38	MIR223	MicroRNA 223	RNA Gene	11.24	DISEASES inferred ¹⁴ ¹⁴
39	MIR27A	MicroRNA 27a	RNA Gene	11.24	DISEASES inferred ¹⁴ ¹⁴
40	MIR92A1	MicroRNA 92a-1	RNA Gene	11.17	DISEASES inferred ¹⁴ ¹⁴
41	MIR141	MicroRNA 141	RNA Gene	11.15	DISEASES inferred ¹⁴ ¹⁴
42	MIR200C	MicroRNA 200c	RNA Gene	11.08	DISEASES inferred ¹⁴ ¹⁴
43	MIR330	MicroRNA 330	RNA Gene	11.08	DISEASES inferred ¹⁴ ¹⁴
44	MIR185	MicroRNA 185	RNA Gene	11.06	DISEASES inferred ¹⁴ ¹⁴
45	MIR590	MicroRNA 590	RNA Gene	11.04	DISEASES inferred ¹⁴ ¹⁴
46	MIR124-1	MicroRNA 124-1	RNA Gene	11.03	DISEASES inferred ¹⁴ ¹⁴
47	MIR486-1	MicroRNA 486-1	RNA Gene	11.01	DISEASES inferred ¹⁴ ¹⁴
48	MIR24-1	MicroRNA 24-1	RNA Gene	11	DISEASES inferred ¹⁴ ¹⁴
49	MIR200B	MicroRNA 200b	RNA Gene	11	DISEASES inferred ¹⁴ ¹⁴
50	MIR125B1	MicroRNA 125b-1	RNA Gene	10.98	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	37762	1	94500000	107000000	Gain	AMY1A	Intestinal disease
2	37786	1	94700000	107200000	Loss	AMY1A	Intestinal disease
3	84156	14	23788159	23802256	Insertion	TGM1	Intestinal disease

Sources

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Sources

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.45	MIR199A1 MIR17 MIR155 MIR145 MIR143
2	DNA damage response (only ATM dependent) ⁷⁴	11.44	TP53 BCL6 APC
3	miRNAs involved in DNA damage response ⁷⁴	11.18	TP53 MIR21 MIR17 MIR145 MIR143
4	miRNAs involvement in the immune response in sepsis ⁷⁴	10.81	MIR21 MIR199A1 MIR155 MIR145 MIR126

Sources

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.6	MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
2	extracellular vesicle	GO:1903561	9.26	MIR21 MIR193A MIR17 MIR126

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.97	TP53 MIR21 MIR199A1 MIR17 MIR155
2	positive regulation of protein kinase B signaling	GO:0051897	9.81	MIR21 MIR199A1 MIR143 MIR126
3	negative regulation of angiogenesis	GO:0016525	9.8	MIR21 MIR193A MIR145 MIR143
4	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.73	MIR31 MIR143 MIR126
5	positive regulation of angiogenesis	GO:0045766	9.72	MIR126 MIR143 MIR199A1 MIR21 MIR31
6	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.65	MIR199A1 MIR196A1 MIR193A
7	miRNA-mediated gene silencing	GO:0035195	9.64	MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
8	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.63	MIR21 MIR199A1 MIR145
9	angiotensin-activated signaling pathway	GO:0038166	9.58	MIR145 MIR143
10	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.57	MIR199A1 MIR17
11	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.55	MIR21 MIR17
12	negative regulation of inflammatory response	GO:0050728	9.55	MIR31 MIR199A1 MIR145 MIR142 MIR126
13	aorta smooth muscle tissue morphogenesis	GO:0060414	9.54	MIR145 MIR143
14	positive regulation of metalloendopeptidase activity	GO:1904685	9.52	MIR21 MIR17
15	regulation of phenotypic switching	GO:1900239	9.43	MIR145 MIR143
16	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.4	MIR17 MIR143
17	positive regulation of cellular response to hypoxia	GO:1900039	9.37	MIR21 MIR145
18	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.35	MIR31 MIR21 MIR17 MIR145 MIR126
19	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.26	MIR145 MIR143

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.73	TP53 MIR31 MIR21 MIR199A1 MIR193A MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.4	MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A